Bionomics Limited, wani kamfani ne na likitancin likitanci, ya sanar da cewa ya fara gwajin gwajin asibiti na Mataki na 2 (Nazarin PREVAIL) don kimanta BNC210 don tsananin jinyar Cutar Tashin hankali (SAD), tare da babban sakamakon da ake tsammanin a ƙarshen 2022.
BNC210 na baka ne, mai mallakar mallaka, mai zaɓin ƙarancin allosteric modulator na α7 nicotinic acetylcholine mai karɓa a cikin haɓakawa don tsananin jiyya na SAD da na yau da kullun na Ciwon Ciwon Jiki na Post-Traumatic Stress (PTSD), tare da Cibiyar Abinci da Magunguna ta Amurka (FDA) nadi mai sauri. ga duka alamun asibiti.
FDA ta share ka'idar Study SAD PREVAIL a cikin Nuwamba 2021, kuma Cibiyar Nazarin Cibiyoyin Kula da Cibiyoyin Amurka ta Tsakiya (IRB) ta ba da izinin ɗabi'a a cikin Disamba 2021. Tare da waɗannan amincewar a wurin, da kuma yarda-matakin rukunin yanar gizo, rukunin yanar gizo na asibiti. a Amurka yanzu ana kunna su kuma an buɗe su don nunawa ga masu yuwuwar mahalarta binciken masu shekaru 18 zuwa 65 tare da alamar SAD mai tsanani. Mahalarta karatun za su buƙaci samun maki na aƙalla 70 akan Siffar Damuwa ta Jama'a ta Liebowitz, wanda shine ma'auni wanda ke tantance matakin jin daɗin jin daɗin majiyyaci a cikin yanayin zamantakewa da aiki. Ana sa ran cewa wuraren 15 zuwa 20 na asibiti a Amurka za su shiga cikin daukar marasa lafiya don wannan binciken.
A cikin wannan bazuwar, makafi biyu, gwajin sarrafa wuribo, BNC210 za a kimanta shi azaman mai mahimmanci, ko kashi ɗaya, jiyya ga marasa lafiya tare da SAD. Masu halartar karatun za a ba su bazuwar zuwa ɗayan ƙungiyoyin jiyya guda uku, 225 mg BNC210, 675 mg BNC210 ko placebo, tare da kusan mahalarta 50 a kowace ƙungiya. Za a ba su da baki kashi ɗaya na jiyya da aka ba su kamar sa'a ɗaya kafin shiga cikin ɗawainiyar ɗabi'a mai tayar da hankali wanda ya haɗa da ƙalubalen magana. Babban makasudin binciken shine kwatanta kowane matakin kashi na BNC210 zuwa placebo akan matakan tashin hankali da aka ruwaito ta amfani da Ma'anar Matsalolin Matsala (SUDS). Makasudin sakandare sun haɗa da wasu ma'auni guda biyu waɗanda ke auna matakan damuwa na mahalarta (Kyakkyawan Abubuwan Damuwa na Jiha da Maganganun Kai Yayin Magana da Jama'a), da kuma kimanta aminci da haƙuri na BNC210 a cikin wannan yawan.
“Rashin damuwa babban nauyi ne ga al’ummominmu kuma kusan manya miliyan 18 suna fama da matsalar Damuwar Jama’a a Amurka kadai. Marasa lafiya yawanci za su fuskanci juriya da tsananin tsoro na al'amuran zamantakewa ko abubuwan da suka shafi aiki lokacin da aka fallasa wa mutanen da ba a sani ba ko kuma wasu na iya bincikarsu. Sau da yawa za su shiga cikin halaye na gujewa don sarrafa tsoronsu, wanda zai iya tsoma baki tare da aiki, ƙara kaɗaici da keɓantawar zamantakewa, da rage ingancin rayuwa. Akwai babban buƙatun da ba a cika buƙatuwa ba don yin aiki da sauri, jiyya da ake buƙata don waɗannan marasa lafiya saboda kawai FDA ta amince da magunguna don Ciwon Tashin Lafiyar Jama'a suna ɗaukar makonni da yawa ko ya fi tsayi kafin su yi tasiri ga alamun. Amincewa da ingantattun jiyya na buƙatu na iya taimaka wa mutanen da ke da matsalar Damuwar Jama'a su shiga ciki, maimakon gujewa, yanayi masu tayar da hankali lokacin da suke buƙata. " In ji masu ba da shawara na Bionomics a Jami'ar California (San Diego) Drs. Charles Taylor (Mataimakin Farfesa, Sashen Kula da Lafiyar Halitta) da Murray Stein (Mai Girma Farfesa, Sashen Kula da Lafiyar Halitta).
"Sabuwar nau'in kwamfutar hannu na BNC210, wanda ke tsomawa cikin sauri kuma ya kai ga mafi girma a cikin jini a cikin kimanin sa'a daya, ana kimanta shi a cikin binciken PREVAIL a matsayin magani na baki kamar yadda ake buƙata ga marasa lafiya SAD don mafi kyawun jimre wa tsammanin tashin hankali-sa jama'a. hulɗa da sauran saitunan jama'a. Muna sa ido don cin gajiyar abubuwan da aka tsara na Fast Track ga duka alamun SAD da alamun jiyya na PTSD, kuma burinmu shine mu ba da rahoton manyan bayanai a ƙarshen 2022 don Nazarin PREVAIL da tsakiyar 2023 don ci gaba da karatun 2b PTSD ATTUNE. Inji Shugaban Hukumar Bionomics, Dr. Errol De Souza.
